A Retrospective Study Assessing Outcomes of Immunomodulatory Radiation Strategies in Combination with Nivolumab Compared with Single Agent Nivolumab in Lung Cancer Patients
Phase of Trial: Phase IV
Latest Information Update: 19 Jun 2018
Price : $35 *
At a glance
- Drugs Nivolumab (Primary)
- Indications Lung cancer
- Focus Adverse reactions; Therapeutic Use
- 19 Jun 2018 New trial record
- 05 Jun 2018 Results assessing post- progression treatment patterns in advanced lung cancer patients treated with nivolumab, presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology.